Home / Open for comment

PROPOSED RULECOMMENTS DUE JANUARY 11, 2027

Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product

Health and Human Services Department / Food and Drug Administration

The Food and Drug Administration (FDA) is proposing to reclassify immunohistochemistry (IHC) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes MVC, NKF, QQT, NQF, PLS, PKW, QUL, QNH, QZJ, SBL, SER, and SHF), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is proposing minor revisions to an existing classification regulation and also proposing a new device classification regulation, along with the special controls that FDA believes are necessary to provide a reasonable assurance of safety and effectiveness for these devices.

Published November 12, 2026Document 2026-23005

How to comment

Comments are due January 11, 2027. Submit through the link above or follow the instructions in the document's ADDRESSES section. Say who you are, how the rule affects you, and what should change, with evidence. Comments are usually public, so leave out anything private.

New to this? Start with our free public-comment guide and example, watch Rulemaking 101 or read How to Comment on Federal Rules.

From the Federal Register as of November 20, 2026. Deadlines can change; the official document governs. Not legal advice.

Know someone following this?

Send them the page so they can check the source and the deadline.